Sector Gamma AS Acquires Shares of 89,964 Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Sector Gamma AS acquired a new stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) during the third quarter, Holdings Channel.com reports. The fund acquired 89,964 shares of the biopharmaceutical company’s stock, valued at approximately $8,811,000. Alexion Pharmaceuticals makes up approximately 1.5% of Sector Gamma AS’s holdings, making the stock its 25th biggest position.

Other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in shares of Alexion Pharmaceuticals by 1.3% during the second quarter. Vanguard Group Inc. now owns 16,649,126 shares of the biopharmaceutical company’s stock valued at $2,180,703,000 after purchasing an additional 211,960 shares in the last quarter. BlackRock Inc. lifted its position in shares of Alexion Pharmaceuticals by 1.2% during the second quarter. BlackRock Inc. now owns 16,225,615 shares of the biopharmaceutical company’s stock valued at $2,125,230,000 after purchasing an additional 199,298 shares in the last quarter. Nuveen Asset Management LLC lifted its position in shares of Alexion Pharmaceuticals by 57,650.8% during the second quarter. Nuveen Asset Management LLC now owns 3,637,144 shares of the biopharmaceutical company’s stock valued at $476,393,000 after purchasing an additional 3,630,846 shares in the last quarter. Northern Trust Corp lifted its position in shares of Alexion Pharmaceuticals by 0.5% during the second quarter. Northern Trust Corp now owns 2,976,327 shares of the biopharmaceutical company’s stock valued at $389,840,000 after purchasing an additional 15,296 shares in the last quarter. Finally, Bank of America Corp DE lifted its position in shares of Alexion Pharmaceuticals by 0.7% during the second quarter. Bank of America Corp DE now owns 2,078,585 shares of the biopharmaceutical company’s stock valued at $272,253,000 after purchasing an additional 13,426 shares in the last quarter. 94.68% of the stock is currently owned by hedge funds and other institutional investors.

ALXN stock traded up $2.74 during mid-day trading on Friday, hitting $110.79. The company had a trading volume of 1,255,600 shares, compared to its average volume of 1,803,421. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.45 and a current ratio of 3.98. Alexion Pharmaceuticals, Inc. has a 12 month low of $92.56 and a 12 month high of $141.86. The firm has a market cap of $23.73 billion, a PE ratio of 15.63, a price-to-earnings-growth ratio of 1.02 and a beta of 1.65. The stock’s fifty day moving average price is $102.45 and its two-hundred day moving average price is $115.69.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Wednesday, October 23rd. The biopharmaceutical company reported $2.79 EPS for the quarter, topping the Zacks’ consensus estimate of $2.47 by $0.32. Alexion Pharmaceuticals had a net margin of 31.05% and a return on equity of 21.21%. The business had revenue of $1.26 billion during the quarter, compared to analysts’ expectations of $1.24 billion. During the same quarter in the previous year, the company earned $2.02 EPS. The business’s quarterly revenue was up 23.0% compared to the same quarter last year. Equities analysts anticipate that Alexion Pharmaceuticals, Inc. will post 9.41 earnings per share for the current year.

A number of research analysts recently weighed in on ALXN shares. William Blair started coverage on shares of Alexion Pharmaceuticals in a research report on Thursday, September 26th. They set an “outperform” rating and a $146.00 price target on the stock. Raymond James raised their price target on shares of Alexion Pharmaceuticals from $168.00 to $170.00 and gave the company an “outperform” rating in a research report on Thursday, October 24th. Royal Bank of Canada reissued a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Wednesday, September 18th. ValuEngine raised shares of Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 2nd. Finally, BidaskClub raised shares of Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, September 11th. One analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have given a buy rating to the company. Alexion Pharmaceuticals has an average rating of “Buy” and an average target price of $159.00.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

See Also: What strategies should day traders use to execute a trade?

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.